These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 23630281)
1. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Mahlknecht G; Maron R; Mancini M; Schechter B; Sela M; Yarden Y Proc Natl Acad Sci U S A; 2013 May; 110(20):8170-5. PubMed ID: 23630281 [TBL] [Abstract][Full Text] [Related]
2. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy. Mahlknecht G; Sela M; Yarden Y Methods Mol Biol; 2015; 1317():3-15. PubMed ID: 26072398 [TBL] [Abstract][Full Text] [Related]
3. An Intelligent DNA Nanorobot with Ma W; Zhan Y; Zhang Y; Shao X; Xie X; Mao C; Cui W; Li Q; Shi J; Li J; Fan C; Lin Y Nano Lett; 2019 Jul; 19(7):4505-4517. PubMed ID: 31185573 [TBL] [Abstract][Full Text] [Related]
4. PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. Kim HJ; Park JY; Lee TS; Song IH; Cho YL; Chae JR; Kang H; Lim JH; Lee JH; Kang WJ PLoS One; 2019; 14(1):e0211047. PubMed ID: 30682091 [TBL] [Abstract][Full Text] [Related]
5. Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs. Lee H; Dam DH; Ha JW; Yue J; Odom TW ACS Nano; 2015 Oct; 9(10):9859-67. PubMed ID: 26335372 [TBL] [Abstract][Full Text] [Related]
6. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas. Sett A; Borthakur BB; Bora U Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267 [TBL] [Abstract][Full Text] [Related]
7. Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy. Jeong HY; Kim H; Lee M; Hong J; Lee JH; Kim J; Choi MJ; Park YS; Kim SC Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371333 [TBL] [Abstract][Full Text] [Related]
8. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth. Xue L; Maihle NJ; Yu X; Tang SC; Liu HY Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359 [TBL] [Abstract][Full Text] [Related]
9. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells. Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334 [TBL] [Abstract][Full Text] [Related]
10. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215 [TBL] [Abstract][Full Text] [Related]
11. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein. Zhang DX; Zhao PT; Xia L; Liu LL; Liang J; Zhai HH; Zhang HB; Guo XG; Wu KC; Xu YM; Jia LT; Yang AG; Chen SY; Fan DM Gut; 2010 Mar; 59(3):292-9. PubMed ID: 19951902 [TBL] [Abstract][Full Text] [Related]
12. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474 [TBL] [Abstract][Full Text] [Related]
13. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433 [TBL] [Abstract][Full Text] [Related]
14. An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. Varmira K; Hosseinimehr SJ; Noaparast Z; Abedi SM J Drug Target; 2014 Feb; 22(2):116-22. PubMed ID: 24098950 [TBL] [Abstract][Full Text] [Related]
15. Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding. Mahlknecht G; Maron R; Schechter B; Yarden Y; Sela M Biochem Biophys Res Commun; 2015 Sep; 465(2):218-24. PubMed ID: 26248137 [TBL] [Abstract][Full Text] [Related]
16. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222 [TBL] [Abstract][Full Text] [Related]
17. Combinatorial Screening of DNA Aptamers for Molecular Imaging of HER2 in Cancer. Zhu G; Zhang H; Jacobson O; Wang Z; Chen H; Yang X; Niu G; Chen X Bioconjug Chem; 2017 Apr; 28(4):1068-1075. PubMed ID: 28122449 [TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138 [TBL] [Abstract][Full Text] [Related]
19. Revealing the molecular interactions of aptamers that specifically bind to the extracellular domain of HER2 cancer biomarker protein: An in silico assessment. Niazi S; Purohit M; Sonawani A; Niazi JH J Mol Graph Model; 2018 Aug; 83():112-121. PubMed ID: 29902673 [TBL] [Abstract][Full Text] [Related]
20. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Dastjerdi K; Tabar GH; Dehghani H; Haghparast A Biotechnol Appl Biochem; 2011; 58(4):226-30. PubMed ID: 21838796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]